We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

and any new IP beyond the three core areas will be available exclusively to CRISPR Therapeutics for human use, and to Bayer for non-human use, such as agricultural applications. Through the JV ...

Group Dinner Meeting to be held in New York on February 5 at 6 pm hosted by Truist. Maximize Your Portfolio with Data Driven Insights:Leverage ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

The company's extensive regulatory and technical expertise further bolsters the therapeutic ... access to best-in-class CRISPR solutions at scale, empowering applications from Discovery to Clinic.

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...